<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185523</url>
  </required_header>
  <id_info>
    <org_study_id>BMT142</org_study_id>
    <secondary_id>78149</secondary_id>
    <secondary_id>12570</secondary_id>
    <nct_id>NCT00185523</nct_id>
  </id_info>
  <brief_title>Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)</brief_title>
  <official_title>Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First or Second Remission or Chronic Myelogenous Leukemia in First and Second Chronic Phase or Accelerated Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the overall and disease free survival of recipients
      who have received G-CSF mobilized stem cells from HLA matched sibling donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic Peripheral Blood Stem Cell Transplantation for Patients with Acute Myelogenous
      Leukemia and Acute Lymphoblastic Leukemia in First Remission or Chronic Myelogenous Leukemia
      in First Chronic Phase
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stemcells from their donors.</measure>
    <time_frame>no known</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">88</enrollment>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <condition>Leukemia</condition>
  <condition>Leukemia Acute Promyelocytic Leukemia (APL)</condition>
  <condition>Leukemia Acute Lymphoid Leukemia (ALL)</condition>
  <condition>Leukemia Chronic Myelogenous Leukemia (CML)</condition>
  <condition>Leukemia Acute Myeloid Leukemia (AML)</condition>
  <condition>Leukemia Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>CML in first Chronic Phase or Accelerated Phase</arm_group_label>
    <description>Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML and ALL in first or second remission</arm_group_label>
    <description>FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic hematopoietic cell transplantation</intervention_name>
    <arm_group_label>CML in first Chronic Phase or Accelerated Phase</arm_group_label>
    <arm_group_label>AML and ALL in first or second remission</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Any patient with one of the following hematologic malignancies in
        whom an allogeneic stem cell transplant is warranted: Specific disease categories include:

          1. acute myelogenous leukemia, 1st or 2nd remission

          2. acute lymphoblastic leukemia, 1st or 2nd remission

          3. chronic myelogenous leukemia, 1st or 2nd CP, accelerated phase 2. Patient age &gt; 1
             month and &lt; 55 yo 3. Patients must have a genotypically HLA identical sibling 4.
             Patient must have adequate function as follows:

        a. total bilirubin &lt;2.5 and SGOT/SGPT &lt;2x normal b. adequate renal function as defined by
        creatinine &lt; 1.5 or a 24 hr creatinine clearance &gt;50 cc/min as determined by the
        Cockroft-Gault formula (to be done if serum creatinine &gt; 1.5) c. DLCO &gt; 60% predicted d.
        radionuclide cardiac scan with ejection fraction &gt;45% 5. Patient must be competent to give
        consent.

        Inclusion criteria (Donor):

          1. HLA identical family member

          2. Donor or guardian must be competent to give consent

          3. Donor must have adequate veins for leukapheresis or agree to placement of central
             venous catheter

        Exclusion Criteria:3.2 Exclusion Criteria (Patient):

          1. Evidence of active infection or active hepatitis

          2. Positive serologies for HIV-1,HIV-2 or hepatitis B surface ag+

          3. Previous allogeneic stem cell/bone marrow transplant

          4. Pregnant or lactating patients

        4 Exclusion criteria (Donor):

          1. Donors who for psychologic, physiologic or medical reasons are unable to tolerate PBSC
             harvest

          2. Donors who are HIV+ or hepatitis B antigen +

          3. History of allergic reaction to G-CSF

          4. Female donors must be post-menopausal or have a negative pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginna Laport</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

